Kenji Sagawa

778 total citations
14 papers, 638 citations indexed

About

Kenji Sagawa is a scholar working on Virology, Molecular Biology and Infectious Diseases. According to data from OpenAlex, Kenji Sagawa has authored 14 papers receiving a total of 638 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Virology, 6 papers in Molecular Biology and 4 papers in Infectious Diseases. Recurrent topics in Kenji Sagawa's work include HIV Research and Treatment (7 papers), HIV/AIDS drug development and treatment (4 papers) and Chemical Synthesis and Analysis (3 papers). Kenji Sagawa is often cited by papers focused on HIV Research and Treatment (7 papers), HIV/AIDS drug development and treatment (4 papers) and Chemical Synthesis and Analysis (3 papers). Kenji Sagawa collaborates with scholars based in Japan and United States. Kenji Sagawa's co-authors include Daikichi Fukushima, Shiro Shibayama, Kenji Maeda, Hiroaki Mitsuya, Reuben P. Siraganian, Toshikazu Miyakawa, Mark Swieter, Teruaki Kimura, Yoshikazu Takaoka and Hideaki Tada and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Virology and Journal of Medicinal Chemistry.

In The Last Decade

Kenji Sagawa

14 papers receiving 623 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kenji Sagawa Japan 11 271 242 190 164 109 14 638
Hidekazu Sawada Japan 11 602 2.2× 480 2.0× 411 2.2× 271 1.7× 106 1.0× 25 1.3k
Eduardo Pauls Spain 20 437 1.6× 469 1.9× 409 2.2× 248 1.5× 38 0.3× 36 1.1k
H. Luke Carter United States 7 324 1.2× 154 0.6× 28 0.1× 186 1.1× 47 0.4× 7 596
Masafumi Kamada Japan 15 277 1.0× 60 0.2× 207 1.1× 38 0.2× 28 0.3× 39 759
Ana M. Mildner United States 8 435 1.6× 85 0.4× 59 0.3× 91 0.6× 76 0.7× 10 592
Sandra L. Gould United States 13 204 0.8× 170 0.7× 281 1.5× 95 0.6× 81 0.7× 15 633
V Brankovan United States 9 326 1.2× 166 0.7× 125 0.7× 290 1.8× 165 1.5× 17 651
Zhaowen Luo United States 14 462 1.7× 157 0.6× 331 1.7× 34 0.2× 34 0.3× 15 816
Takemitsu Nagahata Japan 15 515 1.9× 45 0.2× 128 0.7× 111 0.7× 66 0.6× 24 906
Takanobu Araki Japan 8 250 0.9× 57 0.2× 187 1.0× 60 0.4× 63 0.6× 9 474

Countries citing papers authored by Kenji Sagawa

Since Specialization
Citations

This map shows the geographic impact of Kenji Sagawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenji Sagawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenji Sagawa more than expected).

Fields of papers citing papers by Kenji Sagawa

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenji Sagawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenji Sagawa. The network helps show where Kenji Sagawa may publish in the future.

Co-authorship network of co-authors of Kenji Sagawa

This figure shows the co-authorship network connecting the top 25 collaborators of Kenji Sagawa. A scholar is included among the top collaborators of Kenji Sagawa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenji Sagawa. Kenji Sagawa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Murota, Masayuki, Yoshikazu Takaoka, Hisao Nakai, et al.. (2011). Discovery of 4-[4-({(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl}methyl)phenoxy]benzoic acid hydrochloride: A highly potent orally available CCR5 selective antagonist. Bioorganic & Medicinal Chemistry. 19(13). 4028–4042. 6 indexed citations
2.
Matsunaga, Naoki, Yoshikazu Takaoka, Hisao Nakai, et al.. (2010). Spirodiketopiperazine-based CCR5 antagonist: Discovery of an antiretroviral drug candidate. Bioorganic & Medicinal Chemistry Letters. 21(4). 1141–1145. 7 indexed citations
3.
Hirai, Keisuke, Hiromu Habashita, Yoshikazu Takaoka, et al.. (2010). Discovery of orally available spirodiketopiperazine-based CCR5 antagonists. Bioorganic & Medicinal Chemistry. 18(14). 5208–5223. 11 indexed citations
4.
Hirai, Keisuke, Hiromu Habashita, Yoshikazu Takaoka, et al.. (2009). Spirodiketopiperazine-based CCR5 antagonists: Improvement of their pharmacokinetic profiles. Bioorganic & Medicinal Chemistry Letters. 20(2). 763–766. 14 indexed citations
5.
Habashita, Hiromu, Masaya Kokubo, Nobuyuki Hamanaka, et al.. (2006). Design, Synthesis, and Biological Evaluation of the Combinatorial Library with a New Spirodiketopiperazine Scaffold. Discovery of Novel Potent and Selective Low-Molecular-Weight CCR5 Antagonists. Journal of Medicinal Chemistry. 49(14). 4140–4152. 60 indexed citations
6.
Matsunaga, Naoki, Hiromu Habashita, Yoshikazu Takaoka, et al.. (2006). Spirodiketopiperazine-based CCR5 antagonists: Lead optimization from biologically active metabolite. Bioorganic & Medicinal Chemistry Letters. 17(3). 727–731. 37 indexed citations
7.
Maeda, Kenji, Hirotomo Nakata, Yasuhiro Koh, et al.. (2004). Spirodiketopiperazine-Based CCR5 Inhibitor Which Preserves CC-Chemokine/CCR5 Interactions and Exerts Potent Activity against R5 Human Immunodeficiency Virus Type 1 In Vitro. Journal of Virology. 78(16). 8654–8662. 188 indexed citations
8.
Tani, Kousuke, Atsushi Naganawa, Kenji Sagawa, et al.. (2002). Development of a highly selective EP2-receptor agonist. Part 2: identification of 16-Hydroxy-17,17-trimethylene 9β-chloro PGF derivatives. Bioorganic & Medicinal Chemistry. 10(4). 1107–1114. 13 indexed citations
9.
Tani, Kousuke, Atsushi Naganawa, Kenji Sagawa, et al.. (2002). Development of a highly selective EP2-receptor agonist. Part 1: identification of 16-hydroxy-17,17-trimethylene PGE2 derivatives. Bioorganic & Medicinal Chemistry. 10(4). 1093–1106. 16 indexed citations
10.
Tani, Kousuke, Atsushi Naganawa, Kenji Sagawa, et al.. (2001). Design and Synthesis of a Highly Selective EP2-Receptor Agonist. Bioorganic & Medicinal Chemistry Letters. 11(15). 2025–2028. 37 indexed citations
11.
Maeda, Kenji, Kazuhisa Yoshimura, Shiro Shibayama, et al.. (2001). Novel Low Molecular Weight Spirodiketopiperazine Derivatives Potently Inhibit R5 HIV-1 Infection through Their Antagonistic Effects on CCR5. Journal of Biological Chemistry. 276(37). 35194–35200. 102 indexed citations
12.
Sagawa, Kenji, et al.. (1997). Aggregation of the High Affinity IgE Receptor Results in the Tyrosine Phosphorylation of the Surface Adhesion Protein PECAM-1 (CD31). Journal of Biological Chemistry. 272(20). 13412–13418. 48 indexed citations
13.
Sagawa, Kenji, Teruaki Kimura, Mark Swieter, & Reuben P. Siraganian. (1997). The Protein-tyrosine Phosphatase SHP-2 Associates with Tyrosine-phosphorylated Adhesion Molecule PECAM-1 (CD31). Journal of Biological Chemistry. 272(49). 31086–31091. 95 indexed citations
14.
Suzuki, Akihiko, et al.. (1995). Inhibitory effects of prostaglandin E1.ALPHA.-cyclodextrin (PGE1CD) on dimethylnitrosamine-induced acute liver damage in rats.. Folia Pharmacologica Japonica. 105(4). 221–229. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hidekazu Sawada Breakdown of academic impact, for papers by Eduardo Pauls Breakdown of academic impact, for papers by H. Luke Carter Breakdown of academic impact, for papers by Masafumi Kamada Breakdown of academic impact, for papers by Ana M. Mildner Breakdown of academic impact, for papers by Sandra L. Gould Breakdown of academic impact, for papers by V Brankovan Breakdown of academic impact, for papers by Zhaowen Luo Breakdown of academic impact, for papers by Takemitsu Nagahata Breakdown of academic impact, for papers by Takanobu Araki
Rankless by CCL
2026